Jagsonpal Pharma: Notice on Share Transfer to IEPF & Loss of Share Certificate
Jagsonpal Pharmaceuticals is transferring unclaimed shares to the IEPF by December 28, 2026. A share certificate (No. 231) has been reported lost, with a warning against dealing in it. The company has published these notices in Business Standard (English and Hindi) on September 30, 2026.
This is a standard procedural announcement related to regulatory compliance and the handling of lost share certificates. It is unlikely to have a significant impact on the company's operations or market standing.
The announcement is a routine regulatory filing regarding the transfer of unclaimed shares to the IEPF and the reporting of a lost share certificate. It does not contain any information that would positively or negatively impact the company's financial performance or operations.
Jagsonpal Pharmaceuticals Limited has published notices regarding the transfer of shares to the Investor Education and Protection Fund (IEPF) and the loss of a share certificate. In accordance with Section 124(6) of the Companies Act, 2013, shares for which dividends have remained unclaimed for seven consecutive years will be transferred to the IEPF. Shareholders have been notified on September 29, 2026, and are urged to claim their shares by December 28, 2026. Failure to respond by this date will result in the transfer of these shares to the IEPF authority. The company also reported the loss of share certificate number 231, pertaining to 8000 shares in the name of Kavita Deo. The public is cautioned against dealing with these specific share certificates, and any claims must be lodged within fifteen days of the notice publication, after which duplicate certificates will be issued.
What to do with a filing like this
Jagsonpal Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jagsonpal Pharmaceuticals Limited. Read the original for the full detail.